PMID- 30686257
OWN - NLM
STAT- MEDLINE
DCOM- 20190417
LR  - 20190417
IS  - 1873-4294 (Electronic)
IS  - 1568-0266 (Linking)
VI  - 19
IP  - 1
DP  - 2019
TI  - Peptide Sequence-Dominated Enzyme-Responsive Nanoplatform for Anticancer Drug 
      Delivery.
PG  - 74-97
LID - 10.2174/1568026619666190125144621 [doi]
AB  - Enzymatic dysregulation in tumor and intracellular microenvironments has made 
      this property a tremendously promising responsive element for efficient 
      diagnostics, carrier targeting, and drug release. When combined with 
      nanotechnology, enzyme-responsive drug delivery systems (DDSs) have achieved 
      substantial advancements. In the first part of this tutorial review, changes in 
      tumor and intracellular microenvironmental factors, particularly the enzymatic 
      index, are described. Subsequently, the peptide sequences of various 
      enzyme-triggered nanomaterials are summarized for their uses in various drug 
      delivery applications. Then, some other enzyme responsive nanostructures are 
      discussed. Finally, the future opportunities and challenges are discussed. In 
      brief, this review can provide inspiration and impetus for exploiting more 
      promising internal enzyme stimuli-responsive nanoDDSs for targeted tumor 
      diagnosis and treatment.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Li, Yanan
AU  - Li Y
AD  - First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, 
      030001, China.
FAU - Du, Liping
AU  - Du L
AD  - Institute of Medical Engineering, Department of Biophysics, School of Basic 
      Medical Science, Health Science Center, Xi'an Jiaotong University, No.76 Yanta 
      West Road, Xi'an, Shaanxi 710061, China.
FAU - Wu, Chunsheng
AU  - Wu C
AD  - Institute of Medical Engineering, Department of Biophysics, School of Basic 
      Medical Science, Health Science Center, Xi'an Jiaotong University, No.76 Yanta 
      West Road, Xi'an, Shaanxi 710061, China.
FAU - Yu, Bin
AU  - Yu B
AD  - School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, 
      China.
FAU - Zhang, Hui
AU  - Zhang H
AD  - First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, 
      030001, China.
FAU - An, Feifei
AU  - An F
AD  - Institute of Medical Engineering, Department of Biophysics, School of Basic 
      Medical Science, Health Science Center, Xi'an Jiaotong University, No.76 Yanta 
      West Road, Xi'an, Shaanxi 710061, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Top Med Chem
JT  - Current topics in medicinal chemistry
JID - 101119673
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drug Carriers)
RN  - 0 (Peptides)
RN  - EC 3.1.- (Esterases)
RN  - EC 3.1.- (Phospholipases)
RN  - EC 3.1.1.3 (Lipase)
RN  - EC 3.2.1.- (Glycoside Hydrolases)
RN  - EC 3.4.- (Peptide Hydrolases)
SB  - IM
MH  - Antineoplastic Agents/*administration & dosage/*pharmacology
MH  - Cell Proliferation/drug effects
MH  - Drug Carriers/chemistry/metabolism
MH  - *Drug Delivery Systems
MH  - Drug Screening Assays, Antitumor
MH  - Esterases/chemistry/metabolism
MH  - Glycoside Hydrolases/chemistry/metabolism
MH  - Humans
MH  - Lipase/chemistry/metabolism
MH  - Nanostructures/*chemistry
MH  - Neoplasms/*drug therapy/pathology
MH  - Peptide Hydrolases/chemistry/metabolism
MH  - Peptides/*chemistry/metabolism
MH  - Phospholipases/chemistry/metabolism
OTO - NOTNLM
OT  - DDSs
OT  - Enzyme-responsive
OT  - Peptide
OT  - Sequence
OT  - Targeted drug delivery
OT  - Tumor microenvironment.
EDAT- 2019/01/29 06:00
MHDA- 2019/04/18 06:00
CRDT- 2019/01/29 06:00
PHST- 2018/10/19 00:00 [received]
PHST- 2018/11/06 00:00 [revised]
PHST- 2018/11/23 00:00 [accepted]
PHST- 2019/01/29 06:00 [pubmed]
PHST- 2019/04/18 06:00 [medline]
PHST- 2019/01/29 06:00 [entrez]
AID - CTMC-EPUB-96116 [pii]
AID - 10.2174/1568026619666190125144621 [doi]
PST - ppublish
SO  - Curr Top Med Chem. 2019;19(1):74-97. doi: 10.2174/1568026619666190125144621.